67 results about "Release modulator" patented technology

Methods, formulations, and devices are provided for enhancing drug delivery from a medical device. The method is provided for increasing the rate or quantity of a drug formulation released from an implantable drug delivery device, which method comprises the step of providing a release-modifying agent within or proximate to the implantable drug delivery device, in a manner effective to inhibit gelation, aggregation, or precipitation of the drug formulation being released from the device. The drug formulation and the release-modifying agent may be stored together in at least one reservoir in the implantable drug deliver device. Alternatively, the release-modifying agent may be stored in one or more reservoirs separate from the drug formulation.

The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient.

A sustained release tamsulosin formulation contains tamsulosin, a hydrophobic polymer, a microsphere forming agent and a diluent. The hydrophobic polymers include pH-dependent and pH-independent polymers are used as the release-modulating agent to control the dissolution profile of tamsulosin formulation so that the formulation releases tamsulosin slowly and continuously as the formulation passed through the stomach and gastrointestinal tract.

The invention relates to the field of pharmaceutical preparations and particularly provides a controlled release tablet of metformin hydrochloride and a preparation method of the controlled release tablet. The controlled release tablet provided by the invention contains a tablet core, an insoluble semi-permeable membrane and a drug release micro-pore, wherein the tablet core contains metformin hydrochloride, an adhesive, a release regulator, an absorption accelerant and a lubricating agent. The metformin hydrochloride in the controlled release tablet provided by the invention can be stably released at a constant speed, so that absorption of drugs is more facilitated, and a better in vivo pharmacokinetic curve is realized. Moreover, the preparation method of the controlled release tablet is simple and easy in process, and the technical defect of poor compressibility of the tablet is solved.

The invention relates to an implant and a preparation method thereof. The implant is prepared from components of raw materials in parts by weight as follows: 25-65 parts of a water-insoluble / micro-soluble medicine, 35-75 parts of a water-insoluble polymer and 0-10 parts of a release modifier. The preparation method of the implant comprises steps as follows: (1) the water-insoluble / micro-soluble medicine and the release modifier are dissolved in an organic solvent, and a water-insoluble / micro-soluble medicine solution is obtained; (2) the water-insoluble polymer and the water-insoluble / micro-soluble medicine solution obtained in the step (1) are mixed, the organic solvent is removed and a solid mixture is obtained; (3) the solid mixture obtained in the step (2) is put into a hot melt extruder to be extruded and cut, alternatively, the solid mixture in the step (2) is pressed and formed, and the implant is obtained. With the adoption of the preparation method of the implant, the phenomena of medicine crystallization or aggregation and degradation of the polymer can be effectively reduced or avoided, and long-term release of a medicine is facilitated.

The invention relates to Zuojin helicobacter-pylori-resistant floating tablets and a preparation method thereof. The floating tablets are characterized by comprising 0.2 to 0.75 part of Zuojin alkaloid extract, 0.1 to 0.4 part of hydrophilic macromolecular material, 0.1 to 0.4 part of floating auxiliary agent, 0.01 to 0.1 part of foaming agent, 0.04 to 0.1 part of release regulator and a proper amount of starch, wherein the final total amount is 1 part. The preparation method comprises the following steps of: mixing the Zuojin alkaloid extract, 70 to 90 percent of the hydrophilic macromolecular material, the floating auxiliary agent, the foaming agent, the release regulator and the proper amount of starch in part uniformly, sieving the mixture with a sieve of 60 to 100 meshes, preparing a soft material by using water or 2 to 10 percent polyvinyl pyrrolidone ethanol solution or ethanol solution as an adhesive, sieving with a sieve of 10 to 24 meshes to prepare granules, drying the granules in the air at the temperature of 30 to70 DEG C, and mixing the rest hydrophilic macromolecular material, magnesium stearate in an amount accounting for 1 percent of the total amount and the granules, wherein the total amount is 1 part; and tableting the mixture by using a single-punch tablet press, wherein the weight of each tablet is 500mg, and the hardness is controlled between 30N and 60N. The tablets have the characteristics of constant and complete medicament release, reduced administration amount and administration times, and enhanced treatment effect; and the Zuojin helicobacter-pylori-resistant floating tablets for treating Hp infected stomach diseases are prepared with excellent prescription, compact pharmacological basis, reasonable processes and novel formulation, and are favorable for overcoming the defects of western medicaments, digging the treasure of the traditional Chinese medicine and exerting the treatment advantages of the traditional Chinese medicine.

The invention relates to an anticancer sustained release gel injection with stine drugs, comprising sustained release microspheres with stine drugs, a amphiphilic block copolymer, solvent and releasing moderator; wherein, the mixture of the amphiphilic block copolymer and the solvent possesses sensitive gelation property; after in vivo injection, the injection can be transformed into nonflowing, biodegradable gel insoluble in water; the insoluble gel can release the contained drugs in local tumor for weeks, even months. Intra-tumor injection or local injection can be used to treat different tumors and unresectable tumors, control late complications and the postoperative residual tumor cell recurrent, reinforce the effect of radiotherapy and chemotherapy and the effect of radiotherapy particles; nimustine and carmustine and other stines; the amphiphilic block copolymer is a PLGA-PEG-PLGA copolymer with the molecular weight of PEG 1200-1600 accounting for 20% of the amphiphilic block copolymer weight; in the poly lactide coglycolide copolymer, the molar ratio of glycolide and lactide is 6:1.

Disclosed herein are multiparticulate modified release pharmaceutical compositions comprising: (a) a first portion comprising an active ingredient, at least one surfactant and at least one release modifying agent and (b) a second portion comprising an active ingredient and optionally a release modifying agent. Particularly, the active ingredient in the first portion is a calcium channel blocker and the modified release composition is in the form of a multiparticulate tablet.

The present invention relates to pharmaceutical compositions comprising a peptide that stimulates the release of gonadotropins and sexual steroids. More specifically, the present invention provides pharmaceutical compositions comprising kisspeptin, preferably in the kp-10 form, or derivatives thereof, for use in ovulation cycle inducing and / or infertility treatment programs. The formulations according to the present invention belong to two main groups: injectable solutions and implantable formulations. The injectable solutions according to the present invention can be divided into immediate release solutions and prolonged action solutions. The implantable formulations according to the present invention can be prepared using an RTV silicone elastomer, a rapid vulcanization silicone elastomer or a rapid vulcanization silicone elastomer with a release modulator.

A topical composition comprising a dihydropyridine calcium antagonist, a stiffening agent and a release modifier. The stiffening agent comprises a fatty alcohol, a fatty acid sorbitane ester, or a fatty acid glycerol ester, having a hydrocarbon chain containing 12 to 22 carbon atoms and having a melting point of about 45 to 750° C. The release modifier comprises a fatty alcohol, a fatty alcohol glycol ether, a fatty acid alkyl ester, a fatty acid glycerol ester, or a fatty acid sorbitane ester, having a hydrocarbon chain containing 12 to 18 carbon atoms and having a melting point of about −10 to 400° C. Use of such a composition for the treatment and / or prophylaxis of a dermal or mucosal disorder, preferably an anorectal disorder associated with high anal pressure or anal sphincter spasm.